CheckMate 77T

Prespecified interim analysis results from CheckMate 77T trial of neoadjuvant nivolumab or placebo plus chemotherapy and adjuvant nivolumab or placebo in stage II to IIIB NSCLC, as presented at ESMO Congress 2023 and reported by Clinical Care Options (CCO)

Cancers, Free Full-Text

AACR: Bristol Myers details Opdivo's presurgery lung cancer win

切除可能なステージIIA-IIIB非小細胞肺がんに対する術前ニボルマブ＋

BMS Reports P-III Trial (CheckMate -77T) Results of Neoadjuvant

The earlier, the better? A review of neoadjuvant immunotherapy in

ESMO - European Society for Medical Oncology on LinkedIn: New data

The Cancer News - Authoritative Resource for Everything About

NACLC 22 Educational Session Explores the Rationale for Immune

Shaheenah Dawood on LinkedIn: #nsclc #oncologyresearch